Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 05:37 pm IST
Share
Altimmune, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.362 million compared to USD 0.002 million a year ago. Net loss was USD 20.67 million compared to USD 23.52 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.48 a year ago.
For the nine months, sales was USD 0.389 million compared to USD 0.042 million a year ago. Net loss was USD 56.81 million compared to USD 63.05 million a year ago. Basic loss per share from continuing operations was USD 1.1 compared to USD 1.37 a year ago.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
ALTIMMUNE, INC. 
